data + articles · 1 listed
newest 2017spec sheet8 rows
AVN-322 is an investigational, highly selective 5-HT6 serotonin receptor antagonist developed by Avineuro Pharmaceuticals as a potential cognitive-enhancing treatment for Alzheimer's disease.
- Reversed drug-induced memory impairment in animal studies
- Well tolerated in Phase I human trials with no adverse effects reported
Overview
A clean, well-tolerated 5-HT6 blocker that showed real memory benefits in animals, but the human program quietly stalled before efficacy trials.
Mechanism
AVN-322 selectively blocks the 5-HT6 receptor, a receptor subtype expressed mainly in the brain that normally exerts an inhibitory tone on cholinergic and signaling. By antagonizing 5-HT6, it is thought to boost and release in memory-related circuits; in animal studies it reversed cognitive impairment produced by scopolamine and the -receptor blocker MK-801.
receptor fingerprint
5-HT6 receptorAntagonist
Safetyrisks and cautions, not medical advice
Phase I trials completed in 2010 found AVN-322 well tolerated across the doses tested, with no reported adverse effects. Plans for Phase II efficacy trials were announced but discontinued in 2013, and the compound has not advanced further.
Subjective profileweighing the evidence above
Clean Phase 1 safety and nothing after it; development stopped in 2013 without anyone showing it helps memory in patients. A tidy 5-HT6 story with no result attached, so there is nothing here to chase.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is AVN-322 used for?
It was developed as a potential treatment for Alzheimer's disease and cognitive impairment, aimed at improving memory.
How does AVN-322 work?
It blocks the 5-HT6 serotonin receptor in the brain, which is thought to increase acetylcholine and glutamate signaling important for learning and memory.
Is AVN-322 well-researched?
It has solid preclinical data and a completed, well-tolerated Phase I trial, but it never reached Phase II efficacy testing in patients.
Limitations of the evidence
- Development was discontinued in 2013
Notes and cautions
- Never advanced to Phase II efficacy trials